These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7913085)

  • 1. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.
    Vesalainen SL; Lipponen PK; Talja MT; Alhava EM; Syrjänen KJ
    Int J Cancer; 1994 Jul; 58(2):303-8. PubMed ID: 7913085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
    Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
    Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value.
    Lipponen PK; Eskelinen MJ
    Br J Cancer; 1992 Jul; 66(1):171-6. PubMed ID: 1353364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas.
    Vesalainen S; Lipponen P; Talja M; Kasurinen J; Syrjänen K
    Prostate; 1995 Aug; 27(2):110-7. PubMed ID: 7638083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.
    Visakorpi T; Kallioniemi OP; Heikkinen A; Koivula T; Isola J
    J Natl Cancer Inst; 1992 Jun; 84(11):883-7. PubMed ID: 1350643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators.
    Spires SE; Banks ER; Davey DD; Jennings CD; Wood DP; Cibull ML
    Urology; 1994 May; 43(5):660-6. PubMed ID: 7909398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.
    Aaltomaa S; Lipponen P; Papinaho S; Syrjänen K
    J Cancer Res Clin Oncol; 1993; 119(5):288-94. PubMed ID: 8095051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferating cell nuclear antigen (PCNA) in prostatic invasive adenocarcinoma. Is the proliferation state in the marginal zone of the tumour higher than in the central part?
    Montironi R; Galluzzi CM; Diamanti L; Giannulis I; Scarpelli M; De Nictolis M
    Anticancer Res; 1993; 13(1):129-32. PubMed ID: 8097389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value.
    Bantis A; Giannopoulos A; Gonidi M; Liossi A; Aggelonidou E; Petrakakou E; Athanassiades P; Athanassiadou P
    Cytopathology; 2004 Feb; 15(1):25-31. PubMed ID: 14748788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: no evidence for prognostic value.
    Mangham DC; Rowlands DC; Newbold KM; Reynolds GM; Fielding JW; Hallissey MT
    J Clin Pathol; 1994 May; 47(5):473-4. PubMed ID: 7913101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
    Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters.
    Harper ME; Glynne-Jones E; Goddard L; Wilson DW; Matenhelia SS; Conn IG; Peeling WB; Griffiths K
    Prostate; 1992; 20(3):243-53. PubMed ID: 1374182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial enocarcinoma.
    Heffner HM; Freedman AN; Asirwatham JE; Lele SB
    Eur J Gynaecol Oncol; 1999; 20(1):8-12. PubMed ID: 10422671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma.
    Vesalainen S; Lipponen P
    J Cancer Res Clin Oncol; 1995; 121(7):429-33. PubMed ID: 7635874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei.
    Montironi R; Galluzzi CM; Diamanti L; Giannulis I; Pisani E; Scarpelli M
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):185-92. PubMed ID: 7684168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53.
    Oshiro Y; Fukuda T; Tsuneyoshi M
    Am J Surg Pathol; 1994 Jul; 18(7):712-9. PubMed ID: 7517104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferating cell nuclear antigen in needle biopsy specimens of prostatic carcinoma.
    Naito S; Sakamoto N; Kotoh S; Goto K; Koga H; Hasegawa S; Matsumoto T; Kumazawa J
    Eur Urol; 1994; 26(2):164-9. PubMed ID: 7525294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.